Dynavax Rockets on Study News (DVAX)

Posted in pre-market 
April 15th, 2010

Dynavax Technologies Corporation (NASDAQ: DVAX) is trading up 16.5% at $1.69 on 366,000 shares.  Shares were up a similar amount last night in after-hours trading but had been up over 20% initially.  The news is that its chronic kidney disease study confirmed HEPLISAV’s enhanced seroprotection against HBV infection.  The 52-week range is $0.70 to $3.35 and the average volume is only about 360,000 shares. Before the pop, the market cap was only $78 million.


Comments are closed